Skip to main content

Advertisement

SpringerLink
Log in

A proteomic signature associated to atypical antipsychotic response in schizophrenia patients: a pilot study

  • Short Communication
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

A major hurdle faced by most schizophrenia patients is the poor efficacy of current antipsychotic medications. This stems from a poor understanding of the underlying pathophysiology and the lack of biomarkers for the prediction of a positive medication response. By employing state-of-the-art proteomic analysis of blood plasma from 58 patients who were either drug-naive or drug-free at the time of sample collection, we identified potential biomarkers that were predictive of a positive response after 6 weeks of treatment with antipsychotics. Complement and coagulation cascades were the most over-represented biological pathways among these proteins, consistent with the importance of these processes in schizophrenia. Although preliminary, these findings are novel and may drive future efforts in the development of predictive tests for medication efficacy and thereby have a positive influence on disease outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Tandon R (2010) Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr Res 122:1–23. https://doi.org/10.1016/j.schres.2010.05.025

    Article  PubMed  Google Scholar 

  2. Tandon R (2011) Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry 72(Suppl 1):4–8. https://doi.org/10.4088/JCP.10075su1.01

    Article  CAS  PubMed  Google Scholar 

  3. Martins-de-Souza D, Solari FA, Guest PC et al (2015) Biological pathways modulated by antipsychotics in the blood plasma of schizophrenia patients and their association to a clinical response. NPJ Schizophr 1:15050. https://doi.org/10.1038/npjschz.2015.50

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Sabherwal S, English JA, Föcking M, Cagney G, Cotter DR (2016) Blood biomarker discovery in drug-free schizophrenia: the contribution of proteomics and multiplex immunoassays. Expert Rev Proteomics 13:1141–1155

    Article  CAS  Google Scholar 

  5. Bai ZL, Li XS, Chen GY et al (2018) Serum oxidative stress marker levels in unmedicated and medicated patients with schizophrenia. J Mol Neurosci 66:428–436

    Article  CAS  Google Scholar 

  6. Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S (2012) Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients. Transl Psychiatry 2:e82. https://doi.org/10.1038/tp.2012.3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Suvisaari J, Mantere O, Keinänen J et al (2018) Is it possible to predict the future in first-episode. Psychosis? Front Psychiatry 9:580. https://doi.org/10.3389/fpsyt.2018.00580

    Article  PubMed  PubMed Central  Google Scholar 

  8. Martinuzzi E, Barbosa S, Daoudlarian D et al (2019) Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study. Transl Psychiatry 9(1):20. https://doi.org/10.1038/s41398-018-0366-5

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Aquino A, Alexandrino GL, Guest PC et al (2018) Blood-based lipidomics approach to evaluate biomarkers associated with response to olanzapine, risperidone, and quetiapine treatment in schizophrenia patients. Front Psychiatry 9:209. https://doi.org/10.3389/fpsyt.2018.00209

    Article  PubMed  PubMed Central  Google Scholar 

  10. Garcia S, Silva-Costa LC, Reis-de-Oliveira G et al (2017) Identifying biomarker candidates in the blood plasma or serum proteome. In: Guest PC (ed) Proteomic methods in neuropsychiatric research. Springer, Cham, pp 193–203

    Chapter  Google Scholar 

  11. Jaros JA, Martins de Souza D, Rahmoune H et al (2012) Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls. J Proteomics 76:43–55. https://doi.org/10.1016/j.jprot.2012.05.027

    Article  CAS  PubMed  Google Scholar 

  12. Sekar A, Bialas AR, de Rivera H et al (2016) Schizophrenia risk from complex variation of complement component 4. Nature 530:177–183. https://doi.org/10.1038/nature16549

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Presumey J, Bialas AR, Carroll MC (2017) Complement system in neural synapse elimination in development and disease. Elsevier, Amsterdam pp 53–79

    Google Scholar 

  14. Sellgren CM, Sheridan SD, Gracias J et al (2016) Patient-specific models of microglia-mediated engulfment of synapses and neural progenitors. Mol Psychiatry 22:170–177. https://doi.org/10.1038/mp.2016.220

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. English JA, Lopez LM, O’Gorman A et al (2018) Blood-based protein changes in childhood are associated with increased risk for later psychotic disorder: evidence from a nested case-control study of the ALSPAC longitudinal birth cohort. Schizophr Bull 44(2):297–306. https://doi.org/10.1093/schbul/sbx075

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The Authors thank FAPESP (São Paulo Research Foundation—Grants 2013/08711-3 and 2017/25588-1), CNPq (The Brazilian National Council for Scientific and Technological Development, Grant 302453/2017-2), and Serrapilheira Institute (Grant number Serra-1709-16349).

Author information

Authors and Affiliations

  1. Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), RuaMonteiroLobato, 255, Campinas, SP, 13083-862, Brazil

    Daniel Martins-de-Souza & Paul C. Guest

  2. Instituto Nacional de Biomarcadores em Neuropsiquiatria (INBION), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), São Paulo, Brazil

    Daniel Martins-de-Souza

  3. UNICAMP Neurobiology Center, Campinas, Brazil

    Daniel Martins-de-Souza

  4. Laboratory of Translational Psychiatry, University of Magdeburg, Magdeburg, Germany

    Johann Steiner

  5. Department of Psychiatry and Psychotherapy, University of Magdeburg, Magdeburg, Germany

    Johann Steiner

  6. Center for Behavioral Brain Sciences (CBBS), Magdeburg, Germany

    Johann Steiner

Authors
  1. Daniel Martins-de-Souza
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul C. Guest
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johann Steiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Martins-de-Souza.

Ethics declarations

Conflict of interest

We declare no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (XLS 66 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Martins-de-Souza, D., Guest, P.C. & Steiner, J. A proteomic signature associated to atypical antipsychotic response in schizophrenia patients: a pilot study. Eur Arch Psychiatry Clin Neurosci 270, 127–134 (2020). https://doi.org/10.1007/s00406-019-01002-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-019-01002-3

Keywords

Search

Navigation